Home  |  Contact

Cellosaurus INA-6 (CVCL_5209)

[Text version]

Cell line name INA-6
Synonyms INA6
Accession CVCL_5209
Resource Identification Initiative To cite this cell line use: INA-6 (RRID:CVCL_5209)
Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
Characteristics: Produces Ig kappa.
Characteristics: IL6 dependent.
Doubling time: ~30-50 hours (DSMZ).
Omics: Array-based CGH.
Omics: Deep exome analysis.
Derived from sampling site: Pleural effusion.
Sequence variations Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (DepMap).
Mutation; HGNC; 11998; TP53; Simple; p.Lys132Met (c.395A>T); ClinVar=VCV000376629; Zygosity=Heterozygous (DepMap).
Mutation; HGNC; 11998; TP53; Simple; p.Gln331Ter (c.991C>T); ClinVar=VCV000922893; Zygosity=Heterozygous (DepMap).
Genome ancestry Source: PubMed=30894373

Origin% genome
Native American0.15
East Asian, North2.2
East Asian, South0
South Asian0
European, North63.38
European, South33.82
Disease Plasma cell myeloma (NCIt: C3242)
Multiple myeloma (ORDO: Orphanet_29073)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children:
CVCL_0C40 (INA-6.Tu1)
Sex of cell Male
Age at sampling 80Y
Category Cancer cell line
STR profile Source(s): DSMZ

Penta D9
Penta E7,12

Run an STR similarity search on this cell line
Web pages https://www.keatslab.org/myeloma-cell-lines/hmcl-characteristics

Gramatzki M., Burger R., Trautmann U., Marschalek R., Lorenz H., Hansen-Hagge T.E., Baum W., Bartram C.R., Gebhart E., Kalden J.R.
Two new interleukin-6 dependent plasma cell lines carrying a chromosomal abnormality involving the IL-6 gene locus.
Blood 84 Suppl. 1:173a-173a(1994)

PubMed=10936422; DOI=10.1016/S0145-2126(99)00195-2
Drexler H.G., Matsuo Y.
Malignant hematopoietic cell lines: in vitro models for the study of multiple myeloma and plasma cell leukemia.
Leuk. Res. 24:681-703(2000)

PubMed=11920233; DOI=10.1038/sj.thj.6200075
Burger R., Guenther A., Bakker F., Schmalzing M., Bernand S., Baum W., Duerr B., Hocke G.M., Steininger H., Gebhart E., Gramatzki M.
Gp130 and ras mediated signaling in human plasma cell line INA-6: a cytokine-regulated tumor model for plasmacytoma.
Hematol. J. 2:42-53(2001)

PubMed=17692805; DOI=10.1016/j.ccr.2007.07.003
Keats J.J., Fonseca R., Chesi M., Schop R., Baker A., Chng W.-J., Van Wier S., Tiedemann R., Shi C.-X., Sebag M., Braggio E., Henry T., Zhu Y.-X., Fogle H., Price-Troska T.L., Ahmann G.J., Mancini C., Brents L.A., Kumar S., Greipp P., Dispenzieri A., Bryant B., Mulligan G., Bruhn L., Barrett M.T., Valdez R., Trent J.M., Stewart A.K., Carpten J., Bergsagel P.L.
Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma.
Cancer Cell 12:131-144(2007)

PubMed=18647998; DOI=10.1093/jncimonographs/lgn011
Dib A., Gabrea A., Glebov O.K., Bergsagel P.L., Kuehl W.M.
Characterization of MYC translocations in multiple myeloma cell lines.
J. Natl. Cancer Inst. Monogr. 39:25-31(2008)

PubMed=19621390; DOI=10.1002/ijc.24758
Guenther A., Gordon S., Tiemann M., Burger R., Bakker F., Green J.R., Baum W., Roelofs A.J., Rogers M.J., Gramatzki M.
The bisphosphonate zoledronic acid has antimyeloma activity in vivo by inhibition of protein prenylation.
Int. J. Cancer 126:239-246(2010)

PubMed=22806891; DOI=10.1182/blood-2011-08-371567
Holien T., Vatsveen T.K., Hella H., Waage A., Sundan A.
Addiction to c-MYC in multiple myeloma.
Blood 120:2450-2453(2012)

Chow S.
Targeted capture and sequencing of immunoglobulin rearrangements in multiple myeloma to enable detection of minimal residual disease.
Thesis MSc (2017), University of Toronto, Canada

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3
Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)

Cell line collections DSMZ; ACC-862
Cell line databases/resources Cell_Model_Passport; SIDM01555
DepMap; ACH-000512
Anatomy/cell type resources BTO; BTO:0004745
Biological sample resources BioSample; SAMN10989605
Encyclopedic resources Wikidata; Q54897699
Experimental variables resources EFO; EFO_0005386
Polymorphism and mutation databases Cosmic; 1424216
Cosmic; 1483075
Cosmic; 2081383
Entry history
Entry creation04-Apr-2012
Last entry update16-Dec-2021
Version number22